Latest Posts

27

Mar 24

Partex NV announces collaboration with Althea DRF Lifesciences to provide comprehensive end-to-end services to accelerate drug discovery and development

Frankfurt, Germany; 28 March 2024 – Partex Group, a pioneer in AI-driven drug discovery, announces a collaboration with Althea DRF...
Read More

18

Mar 24

Innovative AI technology in oncology: Partex Group presents results from a pilot project

During the German Cancer Congress 2024 in Berlin, the companies Innoplexus AG /Amrit AG, companies of Partex N.V., presented the...
Read More

Innoplexus wins Horizon Interactive Gold Award for Curia App

Read More

CASE STUDIES & WHITEPAPERS

WHITEPAPER

AUTOIMMUNE INDEX REPORT

Autoimmune Index report provides you with a perspective on the new commercial and clinical opportunities by assessing their clinical innovation aspect. Innoplexus’ AI based CTP engine was leveraged to predict the success probability of clinical assets. Download PDF
WHITEPAPER

INNOPLEXUS’ CTP MODEL

Innoplexus’ CTP model forecasts the outcome of clinical studies and may serve as an early indicator for future stock movements. Download PDF
WHITEPAPER

GENE THERAPY

Gene therapy promises to hold the cure to a number of diseases which, until now, have been considered incurable. By replacing a faulty gene in a patient’s DNA or repairing a defective gene by gene editing, gene therapy can provide a one-time treatment option for diseases such as genetic blindness, muscular dystrophy, blood cancer. Read our recent whitepaper: Advancements in gene therapy – usage of AAV vectors here. Download PDF
WHITEPAPER

EMERGENCE OF CHIMERIC ANTIGEN

Emergence of chimeric antigen receptor-t (CAR-T) cell therapies for cancer treatment Download PDF
CASE STUDY

PIPELINE PRIORITIZATION

Continuously-Updating pipeline prioritization platform

Key Takeaways:

  • Biological Validation: Identifying and validating potential uses of target, pathway, disease and drug candidates.
  • Clinical Trial Valuation: Estimating costs of clinical trials and likelihood of success.
  • Commercial Evaluation: Monitoring competitors and determining commercial opportunity.
Download PDF
CASE STUDY

DATA AS A SERVICE

DAAS APIS to power enterprise artificial intelligence

Key Takeaways:

  • Finding most recent literature from congresses, presentation, clinical trials etc. based on indication and top pathways & targets being studied.
  • Identifying competing drugs and drugs’ details such as pathway, targets, sponsors etc.
  • Finding top investigators, ideal sites, and optimal design parameters for clinical trials.
Download PDF
CASE STUDY

CLINICAL OPTIMIZATION & SITE ENROLLMENT

Identify trial sites & patient enrolment across various parameters

Key Takeaways:

  • Evaluating trial sites based on a client-specific filter system.
  • Identifying & segmenting KOLs across asset classes and involvement.
  • Integrating third-party and enterprise data to gain unique insights.
Download PDF
CASE STUDY

SENTIMENT WATCH

Understanding patient sentiment in real-time

Key Takeaways:

  • Comparing share of voice against competitors across multiple dimensions.
  • Analyzing trend momentum of social sentiments, positive, and negative sentiments share.
  • Gaining insights from social and clinical media around Therapeutic Area (TA), indications, and different drugs.
Download PDF
CASE STUDY

THERAPEUTIC AREA LANDSCAPE DASHBOARDING

Commercial & business intelligence dashboard

Key Takeaways:

  • Centralizing clinical, medical, commercial, and regulatory information in a single dashboard.
  • Monitoring competitor activities and benchmarking performance against theirs.
  • Providing real-time regulatory insights and changes in clinical guidelines.
Download PDF
CASE STUDY

LEAD IDENTIFICATION

Accelerate & Validate lead identification for drug design

Key Takeaways:

  • Identifying efficacious drug candidates with real-world evidence and chemical descriptors.
  • Reducing the cost and time of the demanding lead identification process.
  • Providing access to the largest chemical library for QSAR.
Download PDF
CASE STUDY

KOL DISCOVERY & MANAGEMENT

Identifying key opinion leaders for engagement

Key Takeaways:

  • Identifying top & emerging KOLs by archetypes- thought leader, scientific, speaker, commercial.
  • Discovering the right set of Investigators for your planned clinical trial.
  • Getting comprehensive view into highly influential KOLs, their activities, and associations.
Download PDF
CASE STUDY

TARGET IDENTIFICATION

Accelerating target identification for drug design

Key Takeaways:

  • Identifying optimal targets based on efficacy, safety, clinical and commercial requirements.
  • Narrowing target selection by using in-silico validation.
  • Validating targets based on data of scientific literature.
Download PDF
CASE STUDY

ENDOTYPE RESPONSE & PERSONALIZED MEDICINE

Continuously-updating pipeline prioritization platform

Key Takeaways:

  • Biological Validation: Identifying and validating potential uses of target, pathway, disease and drug candidates.
  • Clinical Trial Valuation: Estimating costs of clinical trials and likelihood of success.
  • Commercial Evaluation: Monitoring competitors and determining commercial opportunity.
Download PDF